Analysts remain skeptical of Amgen's new osteoporosis treatment romosozumab as the Big Biotech releases new data ahead of a potential filing in the next year.
Atlantic Healthcare has raised $24 million in its latest financing, with the founders of Salix Pharmaceuticals and Clinigen Group stumping up much of the cash and Dr. Lorin Johnson joining the company's leadership team.
Last fall, the folks behind Harvard's Blavatnik Biomedical Accelerator took a promising preclinical program from the lab of Matthew Shair and essentially posted a "for sale" sign on it--touting its potential for mounting a fresh line of attack on acute myeloid leukemia with a counterintuitive therapeutic strategy ready for the clinic. The move didn't escape Merck's attention.
At the Barclays Global Healthcare Conference on March 17, Johnson & Johnson highlighted a consumer medical device focus, particularly in emerging markets, alongside 6 device areas of innovation that are expected to undergird growth in the segment for the conglomerate going forward.
Fledgling Norwegian biotech BerGenBio has raised 212 million kroner ($25 million) in a private placement from existing shareholders to help pay for new clinical trials for its lead treatment in blood and lung cancers.
As competition for its hepatitis C drugs intensifies, Gilead Sciences has been working to build up in other therapeutic areas, especially cancer. And while a painful clinical failure for the blockbuster hopeful Zydelig and the high-profile departure of oncology head Philippe Bishop have hamstrung those efforts, Gilead is bullish about its future in the field.
Roche and Kite Pharma are bringing together two of the hottest tickets in oncology research under a new deal announced this week.
As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.
Animal health startup Embark Veterinary is rolling out a DNA testing kit for dogs that will include information about a canine's ancestry and disease risk. The move comes as scientists and the industry target genomic information in dogs to gain more insights about certain diseases.
Scientists have focused on developing new tech to address brain injuries in football players, but now, a group of researchers is thinking bigger picture. Researchers at Harvard University are launching a smartphone app through Apple's ResearchKit that takes a broad look at players' health after they leave the field.